Literature DB >> 8784216

Gabapentin.

M J McLean1.   

Abstract

The amino acid antiepileptic drug (AED) gabapentin (GBP) is indicated for adjunctive use in the treatment of partial seizures with or without becoming secondarily generalized in individuals older than 12 years. GBP was about as potent as phenytoin in the maximal electroshock test, but had a different profile of efficacy than standard antiepileptics in a range of animal models. Possible mechanisms of action include biochemical effects enhancing the ratio of gamma-aminobutyric acid (GABA) to glutamate, ion-channel actions (direct or indirect), and/ or enhancement of nonsynaptic GABA release. The anticonvulsant effect appears to depend on concentration of gabapentin in neurons, presumably by the L-system amino acid transporter that has been implicated in absorption from the gut. Data from studies for U.S. Food and Drug Administration (FDA) approval suggested a direct relationship of clinical response to dose and efficacy did not plateau at the doses used. The maximally effective dose, relationship of efficacy to blood level, and maximum tolerable dose are not yet known conclusively. Lack of significant binding to plasma proteins and lack of liver metabolism contribute to the absence of known limiting drug-drug interactions, particularly with other AEDs. Excretion intact in the urine affords dose adjustment on the basis of creatinine clearance. A half-life of approximately 7 h necessitates multiple doses daily for many individuals. The medication is well tolerated, in general. Side effects tend to be mild to moderate in intensity, most frequently affect the central nervous system, and resolve with time in many individuals. GBP has been prescribed for approximately 70,000 individuals worldwide without untoward incidence of severe systemic toxicity to date. Safety data continue to accumulate. GBP has been labeled category C on the basis of effects on rodent fetuses. Experience with use in pregnant women is limited and human teratogenic effects have not been reported. Data from ongoing monotherapy trials will help to clarify the range of clinical utility of gabapentin.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8784216     DOI: 10.1111/j.1528-1157.1995.tb06001.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  22 in total

1.  Down-regulation of N-type voltage-activated Ca2+ channels by gabapentin.

Authors:  Alfonso Vega-Hernández; Ricardo Felix
Journal:  Cell Mol Neurobiol       Date:  2002-04       Impact factor: 5.046

Review 2.  Treatment of concomitant illnesses in patients receiving anticonvulsants: drug interactions of clinical significance.

Authors:  P Loiseau
Journal:  Drug Saf       Date:  1998-12       Impact factor: 5.606

Review 3.  Dose-related adverse effects of anticonvulsants.

Authors:  A S Troupin
Journal:  Drug Saf       Date:  1996-05       Impact factor: 5.606

Review 4.  Choice and use of newer anticonvulsant drugs in older patients.

Authors:  L J Willmore
Journal:  Drugs Aging       Date:  2000-12       Impact factor: 3.923

Review 5.  A comparative review of the adverse effects of anticonvulsants in children with epilepsy.

Authors:  S J Wallace
Journal:  Drug Saf       Date:  1996-12       Impact factor: 5.606

6.  The use of gabapentin enacarbil in the treatment of restless legs syndrome.

Authors:  Toby C Yaltho; William G Ondo
Journal:  Ther Adv Neurol Disord       Date:  2010-09       Impact factor: 6.570

Review 7.  Antiepileptic drugs and pregnancy outcomes.

Authors:  Bogdan J Wlodarczyk; Ana M Palacios; Timothy M George; Richard H Finnell
Journal:  Am J Med Genet A       Date:  2012-06-18       Impact factor: 2.802

Review 8.  Pharmacokinetics and therapeutic drug monitoring of newer antiepileptic drugs during pregnancy and the puerperium.

Authors:  Torbjörn Tomson; Dina Battino
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 9.  Newer agents for the treatment of painful diabetic peripheral neuropathy.

Authors:  Roy Freeman
Journal:  Curr Diab Rep       Date:  2005-12       Impact factor: 4.810

10.  Once-daily gastroretentive gabapentin for the management of postherpetic neuralgia: an update for clinicians.

Authors:  Gordon Irving
Journal:  Ther Adv Chronic Dis       Date:  2012-09       Impact factor: 5.091

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.